Document Type : Original Article
Authors
1
Department of Biotechnology, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, Egypt, (postal code 62521)
2
Materials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, 62511 Beni-Suef, Egypt, (postal code 62521)
3
The Regional Center for Mycology and Biotechnology (RCMB), Al-Azhar University, 11787, Nasr City, Cairo, Egypt
4
National research center, Cairo Microbial Chemistry department, National Research Centre, 33 El-Buhouth Street,
5
Faculty of Pharmacy, Beni-Suef University, Egypt
6
Materials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences (PSAS), Beni-Suef University, 62511 Beni-Suef, Egypt (postal code 12827)
Abstract
Ceftriaxone is one of the most often prescribed antibiotics for treating the majority of fatal bacterial infections. By forming a nanostructured complex between PAM-18Na polymer and common drugs, one can reduce drug consumption and lessen the adverse effects of the medicine. This study looked at the efficacy of a nanostructured formula containing Ceftriaxone-PAM-18Na for eradicating Streptococcus pneumonia and Klebsiella pneumonia. The dispersion method was applied to prepare the formula. The characterization of the polymer, ceftriaxone, as well as the formula, was done by XRD, FTIR, Zeta-sizer, and Zeta potential. Thermal characterization and morphology detection using a high-resolution transmission electron microscope were done for the formula. Compared to drug or polymer, antibacterial testing of the formula showed the greatest inhibition zones towards Gram-positive as well as Gram-negative pulmonary bacterial infections (18.0 ± 0.32 and 13.0 ± 0.51 mm, respectively). Ultrastructural examination revealed the dramatic effect of the synthesized formula on the structure of Streptococcus pneumonia and Klebsiella pneumonia. The synthesized formula had a cytotoxic concentration of CC50 = 960.12 ± 29.04 µg/mL when tested on MRC-5 mammalian cells, indicating its safety at clinically used concentrations. Our findings suggest that the PAM-18Na polymer can potentially improve Ceftriaxone's ability to eradicate pathogenic lung bacteria as a follow-up treatment option for resistant strains.
Keywords
Main Subjects
)
View on SCiNiTO